PECS II Block and Single Port Robot-assisted Transaxillary Thyroidectomy
Launched by MIN SUK CHAE · Oct 19, 2023
Trial Information
Current as of September 10, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new way to reduce pain after a specific type of thyroid surgery called single-port robot-assisted transaxillary thyroidectomy, which is done using a robotic system. The researchers are focusing on a technique called the PECS II block, where a local anesthetic is injected to help numb the area and reduce pain during and after the surgery. They believe this method could lead to less discomfort and quicker recovery for patients.
To be eligible for this trial, participants need to be between 19 and 60 years old and scheduled for thyroid surgery due to cancer stages T1 or T2, or for nodules that might not be cancerous. It's important that candidates do not have certain conditions, like uncontrolled diabetes or a history of previous neck surgeries. If chosen to participate, patients can expect to receive the PECS II block during their surgery and will be monitored for any pain and complications afterward. This study aims to improve the surgical experience and outcomes for patients undergoing this type of thyroid surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients aged 19 to 60 years who are scheduled to undergo single-port robot thyroidectomy (lobectomy or total thyroidectomy)
- • Patients with cancer stages T1 or T2 (less than 4 cm without invasion of surrounding tissue) when thyroid cancer is suspected in the preoperative examination
- • Patients with nodules with a maximum length of less than 4 cm based on ultrasonography if thyroid cancer is not suspected in the preoperative examination
- • Patients with a BMI greater than or equal to 18.5 and less than 30.0.
- Exclusion Criteria:
- • Patients requiring lateral cervical lymph node dissection
- • pregnant women
- • Uncontrolled diabetes
- • Chronic kidney failure
- • Patients with previous neck surgery
- • Patients with Graves' disease
- • People with chronic alcoholism
- • Patients with vocal cord paralysis before surgery
- • Severe obese patients with a body mass index \>35 kg/m2
- • Patients participating in another clinical trial within 30 days
- • Patients who expect that it will be difficult for medical staff to fill out the questionnaire on their own
- • Patients whose medical staff determines that participation in the study is difficult due to other underlying diseases
About Min Suk Chae
Min Suk Chae is a dedicated clinical trial sponsor committed to advancing medical research and innovation through rigorous and ethical study designs. With a focus on enhancing patient outcomes, the organization collaborates with healthcare professionals and research institutions to conduct comprehensive clinical trials across various therapeutic areas. By prioritizing safety, efficacy, and regulatory compliance, Min Suk Chae aims to contribute valuable insights to the scientific community and improve healthcare solutions for diverse populations. Their expert team is driven by a mission to facilitate the development of novel therapies that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported